Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)
机构：[a]Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland中山大学附属第二医院[b]Sun Yat-sen University Cancer Center, Guangzhou,Guangdong, China[c]The First Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, Zhejiang, China浙江大学医学院附属第一医院[d]Beijing Cancer Hospital, Beijing, China[e]West China Hospital of Sichuan University, Chengdu, Sichuan, China四川大学华西医院[f]Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russian Federation[g]Cherkassy Regional Oncology Dispensary, Cherkassy, Ukraine[h]University Hospital Leuven, Leuven, Belgium[i]Siriraj Hospital, Mahidol University, Bangkok, Thailand[j]Cancer Research Center RAMS – N.N.Blokhin Academy of Medical Science, Moscow, Russian Federation[k]Hospital das Clinicas da Faculdade de Medicina da USP, S~aoPaolo, Brazil[l]Faculty Hospital Brno, Brno, Czech Republic[m]Fudan University Shanghai Cancer Center, Shanghai, China[n]Department of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan[o]Janssen Research andDevelopment, LLC, Raritan, NJ, USA[p]Janssen Research & Development, High Wycombe, Buckinghamshire, UK[q]Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited[r]Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Ticino, Switzerland[s]Chibanishi General Hospital, Chiba, Japan.
The pivotal LYM-3002 study compared frontline rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients for whom stem cell transplantation was not an option. This post hoc subanalysis of the VR-CAP data from LYM-3002 evaluated the effect of bortezomib dose intensity on OS in patients who completed >= 6 cycles of treatment. From the end of cycle 6, patients receiving >= 4.6 mg/m(2)/cycle of bortezomib had significantly longer OS (but not PFS) compared with those receiving <4.6 mg/m(2)/cycle by univariate analysis (HR 0.43 [95% CI: 0.23-0.80]; p = .0059). This association remained significant in multivariate analysis adjusting for baseline patient and disease characteristics (HR 0.40 [95% CI: 0.20-0.79]; p = .008]. Higher bortezomib dose intensity was the strongest predictor of OS in newly diagnosed MCL patients receiving VR-CAP. Clinicaltrials.gov identifier: NCT00722137.
基金：
Janssen Research & Development, LLC; Millennium Pharmaceuticals, Inc.Takeda Pharmaceutical Company Ltd
第一作者机构：[a]Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland[*1]Medical University of Lodz, Department of Hematology, Ciołkowskiego 2 93-510 Lodz, Poland
通讯作者：
通讯机构：[a]Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland[*1]Medical University of Lodz, Department of Hematology, Ciołkowskiego 2 93-510 Lodz, Poland
推荐引用方式(GB/T 7714)：
Tadeusz Robak,Huiqiang Huang,Jie Jin,et al.Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)[J].LEUKEMIA & LYMPHOMA.2019,60(1):172-179.doi:10.1080/10428194.2017.1321750.
APA：
Tadeusz Robak,Huiqiang Huang,Jie Jin,Jun Zhu,Ting Liu...&Franco Cavalli.(2019).Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*).LEUKEMIA & LYMPHOMA,60,(1)
MLA：
Tadeusz Robak,et al."Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)".LEUKEMIA & LYMPHOMA 60..1(2019):172-179
